비알코올 지방간 질환의 약물치료

키워드

참고문헌 (60)

1. Starley BQ, "Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection", Hepatology, 51, pp.1820~1832 (2010)
2. Bellentani S, "Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach", Hepatology, 47, pp.746~754 (2008)
3. Torres DM, "Features, diagnosis, and treatment of nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 10, pp.837~858 (2012)
4. Schuppan D, "Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches", J Gastroenterol Hepatol, 28(1), pp.68~76 (2013)
5. Jourdan T, "Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants", Hepatology, 55, pp.790~799 (2012)
6. Tam J, "Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance", Cell Metab, 16, pp.167~179 (2012)
7. Smith SR, "Multicenter, placebo-controlled trial of lorcaserin for weight management", N Engl J Med, 363, pp.245~256 (2010)
8. Gadde KM, "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial", Lancet, 377, pp.1341~1352 (2011)
9. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
10. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
11. Aithal GP, "Randomized, placebo- controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis", Gastroenterology, 138, pp.1176~1184 (2008)
12. Mahady SE, "The role of thiazolidinediones in non-alcoholic steatohepatitis- a systematic review and meta analysis", J Hepatol, 55, pp.1383~1390 (2011)
13. Kahn SE, "Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT)", Diabetes Care, 31, pp.845~851 (2008)
14. Lewis JD, "Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study", Diabetes Care, 34, pp.916~922 (2011)
15. Lincoff AM, "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials", JAMA, 298, pp.1180~1188 (2007)
16. Lipscombe LL, "Thiazolidinediones and cardiovascular outcomes in older patients with diabetes", JAMA, 298, pp.2634~2643 (2007)
17. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines: management of nonalcoholic fatty liver disease", Clin Mol Hepatol, 19, pp.325~348 (2013)
18. Marchesini G, "Metformin in non-alcoholic steatohepatitis", Lancet, 358, pp.893~894 (2001)
19. Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)
20. Uygun A, "Metformin in the treatment of patients with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 19, pp.537~544 (2004)
21. Torres DM, "Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial", Hepatology, 54, pp.1631~1639 (2011)
22. Vernon G, "Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
23. Musso G, "A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease", Hepatology, 52, pp.79~104 (2010)
24. Bjelakovic G, "Meta-analysis: antioxidant supplements for liver diseases-the Cochrane Hepato-Biliary Group", Aliment Pharmacol Ther, 32, pp.356~367 (2010)
25. Miller ER, "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality", Ann Intern Med, 142, pp.37~46 (2005)
26. Lavine JE, "Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial", JAMA, 305, pp.1659~1668 (2011)
27. Klein EA, "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)", JAMA, 306, pp.1549~1556 (2011)
28. Ratziu V, "A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis", J Hepatol, 54, pp.1011~1019 (2011)
29. Leuschner UF, "High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial", Hepatology, 52, pp.472~479 (2010)
30. Lindor KD, "High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis", Hepatology, 50, pp.808~814 (2009)
31. Xiang Z, "The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review", BMC Gastroenterol, 13, pp.140~ (2013)
32. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
33. Strieter RM, "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline", Biochem Biophys Res Commun, 155, pp.1230~1236 (1988)
34. Zein CO, "Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism", Hepatology, 56, pp.1291~1299 (2012)
35. Zein CO, "Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo- controlled trial", Hepatology, 54, pp.1610~1619 (2011)
36. Van Wagner LB, "Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial", Ann Hepatol, 10, pp.277~286 (2011)
37. Chalasani N, "Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity", Gastroenterology, 126, pp.1287~1292 (2004)
38. Nelson A, "A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial", J Clin Gastroenterol, 43, pp.990~994 (2009)
39. Yokohama S, "Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis", Hepatology, 40, pp.1222~1225 (2004)
40. Georgescu EF, "Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis", World J Gastroenterol, 15, pp.942~954 (2009)
41. Vos MB, "Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field", Curr Opin Lipidol, 25, pp.61~66 (2014)
42. Rabot S, "Germ-free C57BL", 6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism, 2010, pp.24, 4948~4959
43. Zhu L, "Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH", Hepatology, 57, pp.601~609 (2013)
44. Wagnerberger S, "Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model", J Nutr Biochem, 24, pp.531~538 (2013)
45. Okubo H, "Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model", Am J Physiol Gastrointest Liver Physiol, 305, pp.G911~918 (2013)
46. Mencarelli A, "VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation", PLoS One, 7, pp.e45425~ (2012)
47. Wong VW, "Treatment of nonalcoholic steatohepatitis with probiotics: a proof-of-concept study", Ann Hepatol, 12, pp.256~262 (2013)
48. Vrieze A, "Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome", Gastroenterology, 143, pp.913~916.e7 (2012)
49. Parnell JA, "The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance", Liver Int, 32, pp.701~711 (2012)
50. Holst JJ, "Incretin hormones and the satiation signal", Int J Obes (Lond), 37, pp.1161~1168 (2013)
51. Bernsmeier C, "Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic Fatty liver disease", PLoS One, 9, pp.e87488~ (2014)
52. Gupta NA, "Glucagon-like peptide- 1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway", Hepatology, 51, pp.1584~1592 (2010)
53. Svegliati-Baroni G, "Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis", Liver Int, 31, pp.1285~1297 (2011)
54. Trevaskis JL, "Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice", Am J Physiol Gastrointest Liver Physiol, 302, pp.G762~772 (2012)
55. Drucker DJ, "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368, pp.1696~1705 (2006)
56. Iwasaki T, "Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus", Hepatogastroenterology, 58, pp.2103~2105 (2011)
57. Kenny PR, "Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series", Am J Gastroenterol, 105, pp.2707~2709 (2010)
58. Vilsbøll T, "Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials", BMJ, 344, pp.d7771~ (2012)
59. Hollman DA, "Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms", Biochim Biophys Acta, 1821, pp.1443~1452 (2012)
60. Mudaliar S, "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease", Gastroenterology, 145, pp.574~582.e (2013)

관련 논문AI추천